Ticagrelor 90 mg bd vs Clopidogrel 75 mg od: Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.108 | 0.101 | 0.116 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.106 | 0.0994 | 0.114 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.00197 | -0.00833 | 0.0123 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.02 | 0.925 | 1.12 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.02 | 0.917 | 1.14 | log | ClinicalTrials.gov | |
| Number needed to treat, for one more participant with the outcome on Ticagrelor 90 mg bd than on Clopidogrel 75 mg od | 507 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Ticagrelor 90 mg bd | 751 | 6,930 | OG000 | ClinicalTrials.gov | |
| Group 2 | Clopidogrel 75 mg od | 740 | 6,955 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | PRIMARY | ClinicalTrials.gov |
| Title | Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke | ClinicalTrials.gov |
| Description | Participants with CV death, myocardial infarction (MI) or ischemic stroke. If no event, censoring occurs at the minimum of (primary analysis censoring date (PACD), last endpoint assessment date, non-CV death date) | ClinicalTrials.gov |
| Time frame | From randomization to PACD, an average of 2.5 years | ClinicalTrials.gov |
| Population | The population was the full analysis set, which included all randomized patients. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease | ClinicalTrials.gov |
| NCT number | NCT01732822 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Peripheral Artery Disease | ClinicalTrials.gov |
| Interventions | Ticagrelor, Clopidogrel | ClinicalTrials.gov |
| Lead sponsor | AstraZeneca | ClinicalTrials.gov |
| Results first posted | 2017-10-30 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT01732822?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.